| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2017PLoSO..1276784T |
| P356 | DOI | 10.1371/JOURNAL.PONE.0176784 |
| P932 | PMC publication ID | 5409163 |
| P698 | PubMed publication ID | 28453555 |
| P50 | author | Alexander Gintsburg | Q56820635 |
| Vladimir A. Gushchin | Q41544493 | ||
| P2093 | author name string | V G Lunin | |
| A V Demidenko | |||
| A P Tkachuk | |||
| V D Potapov | |||
| P2860 | cites work | A multistage tuberculosis vaccine that confers efficient protection before and after exposure. | Q54391413 |
| Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen | Q57100109 | ||
| TB vaccine failure was predictable | Q74440933 | ||
| TB vaccines; promoting rapid and durable protection in the lung | Q27007497 | ||
| Tuberculosis vaccines: barriers and prospects on the quest for a transformative tool | Q28390218 | ||
| The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity | Q28727776 | ||
| Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial | Q29620144 | ||
| Recombinant bacille Calmette-Guerin coexpressing Ag85b, CFP10, and interleukin-12 elicits effective protection against Mycobacterium tuberculosis. | Q30372324 | ||
| Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. | Q34007101 | ||
| Variation in protection by BCG: implications of and for heterologous immunity | Q34288541 | ||
| Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study | Q34318665 | ||
| Error bars in experimental biology | Q34578493 | ||
| Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial | Q34663035 | ||
| Rv3615c is a highly immunodominant RD1 (Region of Difference 1)-dependent secreted antigen specific for Mycobacterium tuberculosis infection. | Q34804956 | ||
| Subunit vaccine consisting of multi-stage antigens has high protective efficacy against Mycobacterium tuberculosis infection in mice | Q34965575 | ||
| Multi-Stage Tuberculosis Subunit Vaccine Candidate LT69 Provides High Protection against Mycobacterium tuberculosis Infection in Mice | Q35670390 | ||
| The importance of adjuvant formulation in the development of a tuberculosis vaccine | Q35783475 | ||
| Powerful Complex Immunoadjuvant Based on Synergistic Effect of Combined TLR4 and NOD2 Activation Significantly Enhances Magnitude of Humoral and Cellular Adaptive Immune Responses | Q36020045 | ||
| TLR9 mediates S. aureus killing inside osteoblasts via induction of oxidative stress | Q36156486 | ||
| Recombinant domains III of Tick-Borne Encephalitis Virus envelope protein in combination with dextran and CpGs induce immune response and partial protectiveness against TBE virus infection in mice | Q36157927 | ||
| The success and failure of BCG - implications for a novel tuberculosis vaccine | Q36191944 | ||
| A side-by-side comparison of T cell reactivity to fifty-nine Mycobacterium tuberculosis antigens in diverse populations from five continents | Q36338571 | ||
| Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens | Q36500269 | ||
| Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidates | Q36909492 | ||
| Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 Trial | Q37008729 | ||
| Subunit vaccine H56/CAF01 induces a population of circulating CD4 T cells that traffic into the Mycobacterium tuberculosis-infected lung | Q37666257 | ||
| Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guérin vaccination against tuberculosis | Q38135954 | ||
| Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials | Q38171263 | ||
| Targeting the C-type lectins-mediated host-pathogen interactions with dextran | Q38249917 | ||
| Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. | Q38444246 | ||
| Nanoengineering of vaccines using natural polysaccharides. | Q38517950 | ||
| Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study | Q39302030 | ||
| Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial | Q39404079 | ||
| Prime-boost vaccination with Bacillus Calmette Guerin and a recombinant adenovirus co-expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis induces robust antigen-specific immune responses in mice | Q40952119 | ||
| The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial | Q41181011 | ||
| Adjuvants--a classification and review of their modes of action | Q41461373 | ||
| Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection | Q44467383 | ||
| Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers | Q45233558 | ||
| Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. | Q46634611 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e0176784 | |
| P577 | publication date | 2017-04-28 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Multi-subunit BCG booster vaccine GamTBvac: Assessment of immunogenicity and protective efficacy in murine and guinea pig TB models | |
| P478 | volume | 12 |
Search more.